First-Line Axi-Cel Appears Effective in High-Risk Large B-Cell Lymphoma
At a median follow-up of 15.9 months, the median duration of response was not reached.
American Society of Hematology (ASH)
Smartphone App Helps Guide Use of CAR T-Cell, BiTE Therapy
The “myTcell” app is expected to be released in the United States in 2022.
MDS/CMML With KMT2A Rearrangements ‘Should Be Classified as AML’
There was no difference in overall survival between patients with MDS/CMML and those with AML.
PROMISE Study Provides ‘Most Precise’ Estimates of MGUS in High-Risk Patients
The incidence of MGUS was 17% among Black patients.
Triplet Improves Outcomes in Older Patients With FLT3-Mutated Acute Myeloid Leukemia
Response rates and overall survival were superior in the triplet group.
Anakinra Can Prevent Severe CRS, ICANS After CAR T-Cell Therapy
There was 1 case of grade 3 CRS and 1 case of grade 4 CRS.
Novel Agents Lead to Changes in Therapeutic Strategies and Sequencing for CLL
Data were analyzed from patients diagnosed with CLL between 2000 and 2020 from 77 institutions affiliated with the ERIC.
Reinfusion of CAR-T Cells May Prevent Relapse in Acute Lymphoblastic Leukemia
The findings of this study prompted a change in clinical practice.
Brexu-Cel Deemed Safe, Effective for Mantle Cell Lymphoma in Real-World Study
Outcomes were similar to those seen in the ZUMA-2 trial.
COVID-19 Vaccines Less Effective in Patients With Multiple Myeloma
Researchers observed a similar incidence of SARS-CoV-2 infections in vaccinated and unvaccinated patients with multiple myeloma.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ASH 2021 Multiple Myeloma In-depth
Loading... 
Loading...